Small molecule · Inhibitor of signal transducer and activator of transcription 3 (STAT3) · developed by Tvardi Therapeutics
C-188-9 is an orally bioavailable binaphthol-sulfonamide inhibitor of STAT3. It binds the phosphotyrosyl peptide site in the SH2 domain of STAT3, blocking JAK-mediated tyrosine phosphorylation, nuclear translocation and promoter binding. It is studied in hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05440708 | Phase 1/2 | Hepatocellular Carcinoma | Recruiting | TVRD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatocellular Carcinoma
See TVRD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TVRD catalysts and pipeline →